Atossa Therapeutics Inc (NASDAQ: ATOS) established initial surge of 3.15% at $0.89, as the Stock market unbolted on Wednesday, before settling in for the price of $0.86 at the close. Taking a more long-term approach, ATOS posted a 52-week range of $0.55-$1.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 36.92%. Meanwhile, its Annual Earning per share during the time was 36.92%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -16.25%. This publicly-traded company’s shares outstanding now amounts to $129.17 million, simultaneously with a float of $129.12 million. The organization now has a market capitalization sitting at $114.50 million. At the time of writing, stock’s 50-day Moving Average stood at $0.8682, while the 200-day Moving Average is $0.9616.
Atossa Therapeutics Inc (ATOS) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Atossa Therapeutics Inc industry. Atossa Therapeutics Inc’s current insider ownership accounts for 0.04%, in contrast to 26.51% institutional ownership. According to the most recent insider trade that took place on May 21 ’25, this organization’s President & CEO bought 11,239 shares at the rate of 0.88, making the entire transaction reach 9,887 in total value, affecting insider ownership by 13,898. Preceding that transaction, on Mar 26 ’25, Company’s Director bought 10,000 for 0.70, making the whole transaction’s value amount to 7,000. This particular insider is now the holder of 10,257 in total.
Atossa Therapeutics Inc (ATOS) Earnings and Revenue Records
Atossa Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -16.25% and is forecasted to reach -0.27 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -14.47% through the next 5 years, which can be compared against the 36.92% growth it accomplished over the previous five years trading on the market.
Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators
Let’s observe the current performance indicators for Atossa Therapeutics Inc (ATOS). It’s Quick Ratio in the last reported quarter now stands at 12.67.
In the same vein, ATOS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.21, a figure that is expected to reach -0.06 in the next quarter, and analysts are predicting that it will be -0.27 at the market close of one year from today.
Technical Analysis of Atossa Therapeutics Inc (ATOS)
Now, what If we examine the latest scores posted by [Atossa Therapeutics Inc, ATOS]. During the last 5-days, its volume was lower the volume of 0.8 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 19.85% While, its Average True Range was 54.75%.
Raw Stochastic average of Atossa Therapeutics Inc (ATOS) in the period of the previous 100 days is set at 64.51%, which indicates a major rise in contrast to 42.40% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.0506 that was lower than 0.0550 volatility it exhibited in the past 100-days period.
